US Edition
Published • loading... • Updated
Aok Warns Against Higher Drug Prices at the Expense of Insured Persons
Summary by EU-Schwerbehinderung
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
On the occasion of the meeting of the Working Group 3, which is concerned, among other things, with the additional value evaluation of medicines, the chairman of the board of the AOK-Federal Association. Dr. Carola Reimann, as follows. {/mprestriction} "The 66 proposals of the FinanzKommission Gesundheit focus on a revenue-oriented expenditure policy and on the principle of evidence-based. At the same time, the pharmaceutical dialogue will discu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
